Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Litigation Aside Biosimilar Avastin Just Got Cheaper In India

Executive Summary

Another biosimilar version of Roche's anticancer, Avastin (bevacizumab) has just arrived on the Indian market despite the shadow of ongoing litigation. The launch, cheered by some activists, takes prices of biosimilar bevacizumab lower, amid allegations that Roche has been pursuing "vexatious" litigation against Indian competitors.

You may also be interested in...



Biocon’s Avastin Biosimilar To Put The Heat On Competition?

Biocon has launched its biosimilar Avastin in India, intensifying competition on the market. In addition to its ‘affordable’ price, Biocon’s biosimilar Avastin also comes with a novel temperature-sensitive packaging, which it sees as a key differentiator. Roche meanwhile underscored the need to be “very careful” while making packaging changes with biologics.

Biocon’s Avastin Biosimilar To Put The Heat On Competition?

Biocon has launched its biosimilar Avastin in India, intensifying competition on the market. In addition to its ‘affordable’ price, Biocon’s biosimilar Avastin also comes with a novel temperature-sensitive packaging, which it sees as a key differentiator. Roche meanwhile underscored the need to be “very careful” while making packaging changes with biologics.

Indian Avastin Biosimilar Arrives Amid Roche's Charges

Reliance Life Sciences has introduced its biosimilar version of Roche's anticancer, Avastin (bevacizumab), on the Indian market but the Swiss multinational has claimed it is unconvinced of the rigor involved in the regulatory scrutiny of the product.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC065520

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel